A matter of dosage: SF-1 in adrenocortical development and cancer

Annales d'Endocrinologie

Volumn 70, Issue 3, 2009, Pages 148-152

  Doghman, M ^a   Lalli, E ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SF 1; UNCLASSIFIED DRUG;

ADRENAL CANCER; ADRENAL CORTEX; ADRENAL CORTEX TUMOR; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CELL TYPE; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; ORGANOGENESIS; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEROID METABOLISM; STEROID RELEASE; SURVIVAL RATE; TRANSCRIPTION REGULATION; TUMOR GROWTH;

ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; ANIMALS; FERRETS; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; STEROIDOGENIC FACTOR 1;

EID: 67349157055     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2009.02.002     Document Type: Article

References (52)

1. Mesiano S., and Jaffe R.B. Developmental and functional biology of the primate fetal adrenal cortex. Endocr Rev 18 (1997) 378-403
2. Val P., Lefrançois-Martinez A.M., Veyssière G., and Martinez A. SF-1 a key player in the development and differentiation of steroidogenic tissues. Nucl Recept 1 (2003) 8
3. Hammer G.D., Parker K.L., and Schimmer B.P. Minireview: transcriptional regulation of adrenocortical development. Endocrinology 146 (2005) 1018-1024
4. Doghman M., Karpova T., Rodrigues G.A., Arhatte M., De Moura J., Cavalli L.R., et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol 21 (2007) 2968-2987
5. Krylova I.N., Sablin E.P., Moore J., Xu R.X., Waitt G.M., MacKay J.A., et al. Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell 120 (2005) 343-355
6. Li Y., Choi M., Cavey G., Daugherty J., Suino K., Kovach A., et al. Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Mol Cell 17 (2005) 491-502
7. Wang W., Zhang C., Marimuthu A., Krupka H.I., Tabrizizad M., Shelloe R., et al. The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1. Proc Natl Acad Sci U S A 102 (2005) 7505-7510
8. Hammer G.D., Krylova I., Zhang Y., Darimont B.D., Simpson K., Weigel N.L., et al. Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress. Mol Cell 3 (1999) 521-526
9. Lewis A.E., Rusten M., Hoivik E.A., Vikse E.L., Hansson M.L., Wallberg A.E., et al. Phosphorylation of steroidogenic factor 1 is mediated by cyclin-dependent kinase 7. Mol Endocrinol 22 (2008) 91-104
10. Chen W.Y., Juan L.J., and Chung B.C. SF-1 (nuclear receptor 5A1) activity is activated by cyclic AMP via p300-mediated recruitment to active foci, acetylation, and increased DNA binding. Mol Cell Biol 25 (2005) 10442-10453
11. Chen W.Y., Lee W.C., Hsu N.C., Huang F., and Chung B.C. SUMO modification of repression domains modulates function of nuclear receptor 5A1 (steroidogenic factor-1). J Biol Chem 279 (2004) 38730-38735
12. Komatsu T., Mizusaki H., Mukai T., Ogawa H., Baba D., Shirakawa M., et al. Small ubiquitin-like modifier 1 (SUMO-1) modification of the synergy control motif of Ad4 binding protein/steroidogenic factor 1 (Ad4BP/SF-1) regulates synergistic transcription between Ad4BP/SF-1 and Sox9. Mol Endocrinol 18 (2004) 2451-2462
13. Lee M.B., Lebedeva L.A., Suzawa M., Wadekar S.A., Desclozeaux M., and Ingraham H.A. The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification. Mol Cell Biol 25 (2005) 1879-1890
14. Chen W.Y., Weng J.H., Huang C.C., and Chung B.C. Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1). Mol Cell Biol 27 (2007) 7284-7290
15. Campbell L.A., Faivre E.J., Show M.D., Ingraham J.G., Flinders J., Gross J.D., et al. Decreased recognition of SUMO-sensitive target genes following modification of SF-1 (NR5A1). Mol Cell Biol 28 (2008) 7476-7486
16. Zubair M., Ishihara S., Oka S., Okumura K., and Morohashi K. Twostep regulation of Ad4BP/SF-1 gene transcription during fetal adrenal development: initiation by a Hox-Pbx1-Prep1 complex and maintenance via autoregulation by Ad4BP/SF-1. Mol Cell Biol 26 (2006) 4111-4121
17. Luo X., Ikeda Y., and Parker K.L. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 77 (1994) 481-490
18. Sadovsky Y., Crawford P.A., Woodson K.G., Polish J.A., Clements M.A., Tourtellotte L.M., et al. Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side-chain-cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids. Proc Natl Acad Sci U S A 92 (1995) 10939-10943
19. Majdic G., Young M., Gomez-Sanchez E., Anderson P., Szczepaniak L.S., Dobbins R.L., et al. Knockout mice lacking steroidogenic factor 1 are a novel genetic model of hypothalamic obesity. Endocrinology 143 (2002) 607-614
20. Zhao L., Kim K.W., Ikeda Y., Anderson K.K., Beck L., Chase S., et al. Central nervous system-specific knockout of steroidogenic factor 1 results in increased anxiety-like behavior. Mol Endocrinol 22 (2008) 1403-1415
21. Bland M.L., Jamieson C.A., Akana S.F., Bornstein S.R., Eisenhofer G., Dallman M.F., et al. Haploinsufficiency of steroidogenic factor-1 in mice disrupts adrenal development leading to an impaired stress response. Proc Natl Acad Sci U S A 97 (2000) 14488-14493
22. Beuschlein F., Mutch C., Bavers D.L., Ulrich-Lai Y.M., Engeland W.C., Keegan C., et al. Steroidogenic factor-1 is essential for compensatory adrenal growth following unilateral adrenalectomy. Endocrinology 143 (2002) 3122-3135
23. Jameson JL. Editorial: Of mice and men: the tale of steroidogenic factor-1. J Clin Endocrin Metab 2004;89:5927-9.
24. Koch C.A., Pacak K., and Chrousos G.P. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrin Metab 87 (2002) 5367-5384
25. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagneré A.M., et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65 (2005) 7622-7627
26. Michalkiewicz E., Sandrini R., Figueiredo B., Miranda E.C., Caran E., Oliveira-Filho A.G., et al. Clinical and outcome characteristics of children with adrenocortical tumors. An analysis of 254 cases from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 22 (2004) 838-845
27. Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., Lafferty A.R., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 98 (2001) 9330-9335
28. Figueiredo B.C., Sandrini R., Zambetti G.P., Pereira R.M., Cheng C., Liu W., et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 43 (2006) 91-96
29. DiGiammarino E.L., Lee A.S., Cadwell C., Zhang W., Bothner B., Ribeiro R.C., et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9 (2002) 12-16
30. Spencer S.J., Mesiano S., Lee J.Y., and Jaffe R.B. Proliferation and apoptosis in the human adrenal cortex during the fetal and perinatal periods: implications for growth and remodeling. J Clin Endocrin Metab 84 (1999) 1110-1115
31. Figueiredo B.C., Stratakis C.A., Sandrini R., DeLacerda L., Pianovsky M.A., Giatzakis C., et al. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab 84 (1999) 1116-1121
32. Figueiredo B.C., Cavalli L.R., Pianovski M.A., Lalli E., Sandrini R., Ribeiro R.C., et al. Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J Clin Endocrinol Metab 90 (2005) 615-619
33. Pianovski M.A., Cavalli L.R., Figueiredo B.C., Santos S.C., Doghman M., Ribeiro R.C., et al. SF-1 overexpression in childhood adrenocortical tumours. Eur J Cancer 42 (2006) 1040-1043
34. West A.N., Neale G.A., Pounds S., Figueredo B.C., Rodriguez Galindo C., Pianovski M.A., et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67 (2007) 600-608
35. Doghman M., Arhatte M., Thibout H., Rodrigues G., De Moura J., Grosso S., et al. Nephroblastoma overexpressed/cysteine-rich protein 61/connective tissue growth factor/nephroblastoma overexpressed gene-3 (NOV/CCN3), a selective adrenocortical cell proapoptotic factor, is down-regulated in childhood adrenocortical tumors. J Clin Endocrinol Metab 92 (2007) 3253-3260
36. Ratcliffe J., Nakanishi M., and Jaffe R.B. Identification of definitive and fetal zone markers in the human fetal adrenal gland reveals putative developmental genes. J Clin Endocrinol Metab 88 (2003) 3272-3277
37. Planque N., and Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 3 (2003) 15
38. Bielinska M., Kiiveri S., Parviainen H., Mannisto S., Heikinheimo M., and Wilson D.B. Gonadectomy-induced adrenocortical neoplasia in the domestic ferret (Mustela putorius furo) and laboratory mouse. Vet Pathol 43 (2006) 97-117
39. Kananen K., Markkula M., Mikola M., Rainio E.M., McNeilly A., and Huhtaniemi I. 1996 Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin α-subunit promoter/simian virus 40 T-antigen fusion gene: evidence for negative autoregulation of the inhibin α-subunit gene. Mol Endocrinol 10 (1996) 1667-1677
40. Bielinska M., Parviainen H., Porter-Tinge S.B., Kiiveri S., Genova E., Rahman N., et al. 2003 Mouse strain susceptibility to gonadectomy-induced adrenocortical tumor formation correlates with the expression of GATA-4 and luteinizing hormone receptor. Endocrinology 144 (2003) 4123-4133
41. Rilianawati, Paukku T., Kero J., Zhang F.P., Rahman N., Kananen K., et al. Direct luteinizing hormone action triggers adrenocortical tumorigenesis in castrated mice transgenic for the murine inhibin α-subunit promoter/simian virus 40 T-antigen fusion gene. Mol Endocrinol 12 (1998) 801-809
42. Bielinska M., Genova E., Boime I., Parviainen H., Kiiveri S., Leppaluoto J., et al. Gonadotropin-induced adrenocortical neoplasia in NU/J nude mice. Endocrinology 146 (2005) 3975-3984
43. Johnsen I.K., Slawik M., Shapiro I., Hartmann M.F., Wudy S.A., Looyenga B.D., et al. Gonadectomy in mice of the inbred strain CE/J induces proliferation of sub-capsular adrenal cells expressing gonadal marker genes. J Endocrinol 190 (2006) 47-57
44. Bernichtein S., Petretto E., Jamieson S., Goel A., Aitman T.J., Mangion J.M., et al. Adrenal gland tumorigenesis after gonadectomy in mice is a complex genetic trait driven by epistatic loci. Endocrinology 149 (2008) 651-661
45. Karpova T., Presley J., Manimaran R.R., Scherrer S.P., Tejada L., Peterson K.R., et al. A Ftz-F1-containing yeast artificial chromosome recapitulates expression of steroidogenic factor 1 in vivo. Mol Endocrinol 19 (2005) 2549-2563
46. Looyenga B.D., and Hammer G.D. Origin and identity of adrenocortical tumors in inhibin knockout mice: implications for cellular plasticity in the adrenal cortex. Mol Endocrinol 20 (2006) 2848-2863
47. Berruti A., Ferrero A., Sperone P., Daffara F., Reimondo G., Papotti M., et al. Emerging drugs for adrenocortical carcinoma. Expert Opin Emerg Drugs 13 (2008) 497-509
48. Del Tredici A.L., Andersen C.B., Currier E.A., Ohrmund S.R., Fairbain L.C., Lund B.W., et al. Identification of the first synthetic steroidogenic factor 1 inverse agonists: pharmacological modulation of steroidogenic enzymes. Mol Pharmacol 73 (2008) 900-908
49. Madoux F., Li X., Chase P., Zastrow G., Cameron M.D., Conkright J.J., et al. Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening. Mol Pharmacol 73 (2008) 1776-1784
50. Betz M.J., Shapiro I., Fassnacht M., Hahner S., Reincke M., Beuschlein F., et al. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab 90 (2005) 3886-3896
51. Doghman M., Cazareth J., and Lalli E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab 93 (2008) 3222-3225
52. Barlaskar F.M., Spalding A.C., Heaton J.H., Kuick R., Kim A.C., Thomas D.G., et al. Preclinical targeting of the type 1 insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94 (2009) 204-212